Purple Biotech (Purple Biotech) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Purple Biotech Days Payable?

Purple Biotech's average Accounts Payable for the three months ended in Dec. 2023 was $3.06 Mil. Purple Biotech's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Purple Biotech's Days Payable or its related term are showing as below:

PPBT's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 146.16
* Ranked among companies with meaningful Days Payable only.

Purple Biotech's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00). stayed the same

Purple Biotech Days Payable Historical Data

The historical data trend for Purple Biotech's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech Days Payable Chart

Purple Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Purple Biotech Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Purple Biotech's Days Payable

For the Biotechnology subindustry, Purple Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Purple Biotech's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Purple Biotech's Days Payable distribution charts can be found below:

* The bar in red indicates where Purple Biotech's Days Payable falls into.

Purple Biotech Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Purple Biotech's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (2.132	+	3.532)	/	2 )	/	0	*	365
=	2.832					/	0	*	365
=	N/A

Purple Biotech's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (2.593	+	3.532)	/	2 )	/	0	*	365 / 4
=	3.0625					/	0	*	365 / 4
=	N/A

Purple Biotech Days Payable Related Terms

Thank you for viewing the detailed overview of Purple Biotech's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Purple Biotech (Purple Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (NAS:PPBT) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

PPBT:Israel 1YI1:Germany

Address

4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104

Website

https://www.purple-biotech.com

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.